Citigroup
CRSP icon

Citigroup’s CRISPR Therapeutics CRSP Stock Holding History

Citigroup’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.78M Sell
51,000
-28,000
-35% -$1.48M ﹤0.01% 2662
2026
Q1 		$3.76M Buy
+79,000
New +$4.17M ﹤0.01% 2185
2025
Q3 		– Sell
-55,000
Closed -$2.68M – 6126
2025
Q2 		$2.68M Hold
55,000
– – ﹤0.01% 2394
2025
Q1 		$1.87M Buy
55,000
+34,600
+170% +$1.47M ﹤0.01% 2765
2024
Q4 		$803K Buy
+20,400
New +$963K ﹤0.01% 3527
2023
Q2 		– Sell
-30,000
Closed -$1.36M – 5586
2023
Q1 		$1.36M Sell
30,000
-50,000
-63% -$2.43M ﹤0.01% 2316
2022
Q4 		$3.25M Buy
80,000
+10,000
+14% +$530K ﹤0.01% 1720
2022
Q3 		$4.58M Buy
+70,000
New +$5.07M ﹤0.01% 1603
2021
Q1 		– Sell
-96,300
Closed -$14.7M – 6439
2020
Q4 		$14.7M Buy
96,300
+68,800
+250% +$8.13M 0.01% 1256
2020
Q3 		$2.3M Sell
27,500
-5,700
-17% -$506K ﹤0.01% 2529
2020
Q2 		$2.44M Sell
33,200
-10,400
-24% -$608K ﹤0.01% 2585
2020
Q1 		$1.85M Sell
43,600
-6,800
-13% -$351K ﹤0.01% 2552
2019
Q4 		$3.07M Buy
50,400
+18,800
+59% +$1.03M ﹤0.01% 2512
2019
Q3 		$1.29M Buy
31,600
+17,600
+126% +$841K ﹤0.01% 3347
2019
Q2 		$659K Buy
14,000
+4,800
+52% +$192K ﹤0.01% 4133
2019
Q1 		$329K Sell
9,200
-10,700
-54% -$370K ﹤0.01% 4615
2018
Q4 		$569K Buy
19,900
+14,600
+275% +$508K ﹤0.01% 3987
2018
Q3 		$235K Buy
+5,300
New +$278K ﹤0.01% 5090

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citigroup's CRSP Position: Q2 2026 in Review

Citigroup increased its CRISPR Therapeutics (CRSP) stake by 420% in Q2 2026, buying an estimated $4.87M and bringing the position to 114,316 shares worth $6.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1961.

Citigroup first reported a position in CRSP in Q1 2017 and has held it in 37 quarters since. The position peaked at $8.64M in Q1 2023. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Citigroup held 114,316 shares of CRISPR Therapeutics worth $6.23M as of Q2 2026.
  • Citigroup bought 92,346 CRISPR Therapeutics shares in Q2 2026, an estimated $4.87M.
  • CRISPR Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1961 holding.
  • Citigroup first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 37 quarters since.
  • Citigroup's CRISPR Therapeutics position peaked at $8.64M in Q1 2023.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.